Have you or a loved one suffered from excessive bleeding problems as a result of taking Xarelto? If your answer is yes, then there is a good chance that you’re eligible for a Xarelto lawsuit.
What is Xarelto?
Xarelto (Rivaroxaban) is used as a blood thinner to prevent a certain type of blood clotting called deep vein thrombosis (DVT). The drug is manufactured by Bayer and Johnson & Johnson. It was approved by the U.S. Food and Drug Administration in 2011.
For a few years, Xarelto has been perceived as a better blood thinner than its competitors. While that might be true, it is equally more dangerous because unlike other blood thinners, Xarelto can cause excessing bleeding that can not be stopped by a doctor and can prove fatal.
Side Effects of Xarelto
Like any other drug, Xarelto comes with its own set of side effects. Almost all anticoagulant drugs can potentially cause internal bleeding (hemorrhaging). But unlike other anticoagulants, such as warfarin, there is no antidote for internal bleeding caused by Xarelto. The manufacturers have not advised the users explicity to undergo regular blood monitoring tests that may help prevent the internal bleeding.
Some of the side effects associated with Xarelto include:
- Excessive bleeding
- Abdominal hemorrhages
- Adrenal bleeding
- Bleeding nose
- Epidural hematoma
- Bleeding gums
- Coughing up blood
- Serious allergic reaction (very rare)
- Back pain
The lawsuits allege that the manufacturers of Xarelto were negligent in many ways. Some of the allegations in the lawsuits are:
- The manufacturers did not disclose the non-existence of an antidote for bleeding caused by Xarelto.
- The labeling of Xarelto does not adequately disclose the risks associated with the drug.
- The manufacturers intentionally concealed the knowledge of Xarelto’s potentially life-threatening side effects.
Xarelto Lawsuit Eligibility
Patients who took Xarelto and experienced bleeding, strokes or death could be eligible for a Xarelto lawsuit. Family members of a patient who died while taking Xarelto are also potentially eligible.